Loading...
XHKG2172
Market cap659mUSD
Dec 27, Last price  
8.87HKD
1D
0.34%
1Q
3.50%
IPO
-63.80%
Name

MicroPort NeuroTech Ltd

Chart & Performance

D1W1MN
XHKG:2172 chart
P/E
33.08
P/S
7.23
EPS
0.25
Div Yield, %
0.00%
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
666m
+21.61%
183,720,000221,923,000382,799,000547,350,000665,624,000
Net income
146m
P
46,975,00045,287,00024,170,000-21,765,000145,548,000
CFO
154m
-31.29%
56,650,00047,234,000157,406,000223,798,000153,778,000
Dividend
Sep 10, 20240.08 HKD/sh
Earnings
Mar 27, 2025

Profile

MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.
IPO date
Jul 15, 2022
Employees
575
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
665,624
21.61%
547,350
42.99%
382,799
72.49%
Cost of revenue
485,837
432,075
285,409
Unusual Expense (Income)
NOPBT
179,787
115,275
97,390
NOPBT Margin
27.01%
21.06%
25.44%
Operating Taxes
27,470
20,352
7,733
Tax Rate
15.28%
17.66%
7.94%
NOPAT
152,317
94,923
89,657
Net income
145,548
-768.73%
(21,765)
-190.05%
24,170
-46.63%
Dividends
(344,002)
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
23,786
24,725
27,993
Long-term debt
98,934
145,763
191,403
Deferred revenue
19,136
18,124
Other long-term liabilities
35,567
7,894
3,253
Net debt
(985,651)
(812,942)
(577,412)
Cash flow
Cash from operating activities
153,778
223,798
157,406
CAPEX
(202,603)
(47,945)
(57,980)
Cash from investing activities
(233,159)
(344,523)
(186,790)
Cash from financing activities
(33,276)
329,537
200,746
FCF
322,082
(45,753)
(50,829)
Balance
Cash
1,084,358
1,134,703
593,287
Long term investments
24,013
(151,273)
203,521
Excess cash
1,075,090
956,062
777,668
Stockholders' equity
260,460
107,860
60
Invested Capital
1,474,718
1,471,597
(48,073)
ROIC
10.34%
13.34%
61.66%
ROCE
10.36%
7.30%
8.18%
EV
Common stock shares outstanding
582,658
517,543
582,658
Price
12.24
-46.67%
22.95
 
Market cap
7,131,734
-39.96%
11,877,612
 
EV
6,148,829
11,077,518
EBITDA
235,879
171,976
129,113
EV/EBITDA
26.07
64.41
Interest
3,460
99,277
45,200
Interest/NOPBT
1.92%
86.12%
46.41%